Preoperatif Nötrofil Lenfosit Oranının Açık Prostatektomi Yapılan Benign Prostat Hiperplazili Hastalarda Perioperatif Sonuçlara Etkisi

Öz

Amaç: Çalışmanın amacı semptomatik benign prostat hiperplazisi BPH nedeniyle açık prostatektomi yapılan hastalarda preoperatif nötrofil lenfosit oranının NLO perioperatif sonuçlar üzerine etkisinin değerlendirilmesidir.Gereç ve Yöntemler: Aralık 2012 ve Kasım 2015 arasında BPH nedeniyle açık prostatektomi olan hastaların demografik, perioperatif ve postoperatif verileri retrospektif olarak değerlendirildi. Demografik özellikler olarak yaş, komorbiditeler, prostat hacmi ml , PSA ng/dl , serum nötrofil ve lenfosit değerleri ve oranı; intraoperatif özellikler olarak operasyon süresi dk. , tahmini kan kaybı ml , kan transfüzyon oranı; postoperatif özellikler olarak hospitalizasyon süresi ile drenaj kateterinin ve üretral sondanın kalış süresi, kan transfüzyon miktarı ve komplikasyonlar kaydedildi. Delta haemoglobin Preoperatif Hemoglobin – Postoperatif Hemoglobin ölçüldü. Komplikasyonlar Clavien sınıflamasına göre değerlendirildi. Anlamlı p değeri p

Anahtar Kelimeler

• Benign prostat hiperplazisi, Nötrofil lenfosit oranı, Operasyon süresi, Prostatektomi, Cerrahi kan kaybı

Impact of Preoperative Neutrophil to Lymphocyte Ratio in Patients with Benign Prostate Hyperplasia Undergo Open Prostatectomy: A Pilot Study

Abstract

Objective: To evaluate preoperative Neutrophil-to-lymphocyte ratio NLR in patients who underwent open prostatectomy OP for symptomatic BPH.Material and Methods: Our database were investigated for OP between December 2012 and November 2015. Demographic, perioperative, and postoperative data were recorded. Delta haemoglobin was calculated as preoperative haemoglobin – post-operative haemoglobin . Complications was assessed according to Clavien Classification. Significant p was p

Keywords

• Benign prostatic hyperplasia, Neutrophil to lymphocyte ratio, Operative time, Prostatectomy, Surgical blood loss

References

1. Agarwal A, Eryuzlu LN, Cartwright R, Thorlund K, Tammela TL, Guyatt GH, Auvinen A, Tikkinen KA. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 2014; 65: 1211-7.
2. Michel MC, Vrydag W. Alpha1-, alpha2- and beta- adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147 Suppl 2: S88-S119.
3. Akin Y, Gulmez H, Ucar M, Yucel S. The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term. Int Urol Nephrol 2013; 45: 45-51.
4. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54: 419-26.
5. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: Benign prostatic hyperplasia. J Urol 2008; 179: S75-S80.
6. Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 2014; 15(12):463.
7. Kaplan SA. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. J Urol 2016; 195: 689-92.
8. Gregory AD, Houghton AM. Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res 2014; 71: 2411-6.

9. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003; 36: 1359-67.
10. Brown CT, van der Meulen J, Mundy AR, O’Flynn E, Emberton M. Defining the components of a self- management programme for men with uncomplicated lower urinary tract symptoms: A consensus approach. Eur Urol 2004; 46: 254-62.
11. Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1998; 1: 332-5.
12. Roehrborn CG. Three months’ treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006; 9: 121-5.
13. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001; 58: 717-22.
14. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172(4 Pt 1): 1399-1403.
15. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004.
16. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.
17. Reich O, Gratzke C, Stief CG. Techniques and long- term results of surgical procedures for BPH. Eur Urol 2006; 49:970-8.
18. http://uroweb.org/guideline/treatment-of-non- neurogenic-male-luts/#note_180. (accessed 16 May 2016)
19. Dindo D, Clavien PA. Interest in morbidity scores and classification in general surgery. Cir Esp 2009; 86:269-71.
20. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology 1998; 51 Suppl 4A: 23–31.
21. Yassin M, Prasad SM, Hashim H. Surgery for benign prostatic obstruction. In: Keane TE, Graham SD JR, eds. Glenn’s urologic surgery. 7th ed. Philadelphia: Wolters Kluwer, 2010; 166-74.
22. Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1618-31.
23. Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 2016; 13: 108-19.
24. Fujita K, Imamura R, Tanigawa G, Nakagawa M, Hayashi T, Kishimoto N, Hosomi M, Yamaguchi S. Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis 2012; 15: 386-90.
25. Ngugi PM, Saula PW. Open simple prostatectomy and blood transfusion in Nairobi. East Afr Med J 2007; 84 Suppl 9: S12-S23.
26. Spence RK. Emerging trends in surgical blood transfusion. Semin Hematol 1997; 34 Suppl 2: 48-53.
27. Chang SS, Duong DT, Wells N, Cole EE, Smith JA Jr, Cookson MS. Predicting blood loss and transfusion requirements during radical prostatectomy: The significant negative impact of increasing body mass index. J Urol 2004; 171: 1861–5.